SecBot SecBot
PRESS-RELEASE ·Filed Jul 16, 2026

GRFS

Grifols, S.A.
NEUTRAL
Impact 4/10
Horizonmonths Processed4mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

No near-term stock-moving catalyst. The Phase 3 trials are early-stage with enrollment just beginning; investors should monitor enrollment updates and eventual data readouts (likely 2-3 years out). Strong XEMBIFY growth (60% YoY) supports the label expansion rationale but is already reflected in current estimates.

DirectionNeutral
Confidencehigh
Horizonmonths

GAMUNEX-C

● Neutral Named in this press release
Impact
Phase
Approved (marketed); new Phase 3 label-expansion trial (SIGMA) just begun enrolling
Time to market
Already on the market (approved and commercialized). Label expansion into secondary immunodeficiency is estimated years away — readouts likely 2-3 years out per company commentary.
Next catalyst
None dated

What to watchFor Grifols (GRFS), Gamunex-C is a core revenue asset but not a near-term stock catalyst, the share-price drivers in the next ~12 months are company-wide (SPARTA Prolastin-C topline expected by end-2026, quarterly results), not Gamunex-C-specific. Watch SIGMA/XPERT enrollment updates for optionality, but treat the label-expansion payoff as a 2028+ event. Note the tape is mixed: positive analyst consensus and Q2 2026 13F accumulation by several managers, but also high short-volume flow and multiple 13F trims/exits.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$7.33
T+0 close · Jul 16, 2026 · via day close
Latest settled
+1.77%
T+60 · $7.46
Vs SPY
−1.94%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 16 $7.33entry
  2. T+1 · 4mo ago −0.82%α +0.17% · $7.27
  3. T+5 · 4mo ago +2.86%α +4.54% · $7.54
  4. T+20 · 3mo ago +8.19%α +4.57% · $7.93
  5. T+60 · 6w ago +1.77%α −1.94% · $7.46
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Grifols announced first patient dosing in two Phase 3 trials (SIGMA and XPERT) seeking U.S. label expansion for its immunoglobulin products GAMUNEX-C (IVIg) and XEMBIFY (SCIg) into secondary immunodeficiency and CIDP, respectively. The trials are early-stage with no near-term financial impact; the company highlighted XEMBIFY's 60% YoY growth in 2025 as a tailwind for the franchise.

Key Facts

  • First patients dosed in two Phase 3 trials: SIGMA (GAMUNEX-C for SID in hematologic cancers) and XPERT (XEMBIFY for CIDP non-inferiority vs GAMUNEX-C).
  • XEMBIFY grew nearly 60% year over year in 2025, indicating strong demand for the SCIg product.
  • SIGMA targets a population of >1 million U.S. patients with CLL, MM, and NHL; XPERT targets ~60,000 U.S. CIDP patients.
  • Both trials are open-label, multicenter studies with small sample sizes (50 and 40 patients respectively).

Financial Impact

No financial data disclosed; potential label expansion could drive incremental Ig franchise revenue but is years away from commercialization.

Risk Factors

  • Trial failure or enrollment delays could delay label expansion and competitive positioning.
  • Regulatory or safety issues could arise during the trials, including thrombotic events common to Ig products.
  • Competing Ig therapies (e.g., from CSL Behring, Takeda) may limit market share gains even if labels expand.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3328383

Track record

7 reports on GRFS

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $8.51 to $8.69 Now $8.73 +2.59% ▲ +2.12% +2.04% vs SPY
  2. Nov 2, 202614d ago 6-K Bullish 6/10 Entry $8.51 to $8.69 Now $8.73 +2.59% ▲ +2.12% +2.04% vs SPY
  3. Aug 10, 202614w ago Press Release Neutral 4/10 Entry $8.05 to $7.77 Now $8.73 +8.45% ▼ −3.48% −3.43% vs SPY
  4. Jul 30, 202615w ago 6-K Neutral 2/10 Entry $8.20 to $7.83 Now $8.73 +6.46% ▼ −4.51% −8.13% vs SPY
  5. Jul 16, 202617w ago Press Release Neutral 4/10 Viewing Entry $7.33 to $7.54 Now $8.73 +19.10% ▲ +2.86% +4.54% vs SPY
  6. Jun 18, 202621w ago 6-K Neutral 3/10 Entry $7.28 to $7.39 Now $8.73 +19.92% ▲ +1.51% +3.58% vs SPY
  7. Mar 17, 202634w ago Press Release Bullish 7/10 Entry $8.02 to $7.60 Now $8.73 +8.85% ▼ −5.24% −2.58% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens Wed (11h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 16, 2026